Clinical trial
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon…
NCT00118365 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118365 |
|---|---|
| Title | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps |
| Official title | A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Precancerous Condition |
| Intervention type | Drug, Other |
| Interventions | placebo, eflornithine, sulindac, laboratory biomarker analysis |
| Enrollment | 375 |
| Start date | Jul 1, 1998 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | Jan 22, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: